Editorial: Clostridium difficile infection: Yet another predictor of poor outcome in cirrhosis

American Journal of Gastroenterology

Volumn 105, Issue 1, 2010, Pages 114-116

  Garcia Tsao, Guadalupe ^a,b   Surawicz, Christina M ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; COTRIMOXAZOLE; NORFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG INDICATION; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COMORBIDITY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITAL CHARGES; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROTON PUMP INHIBITORS; RISK FACTORS; UNITED STATES; WISCONSIN;

EID: 73849145731     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.604     Document Type: Review

References (31)

1. Kuipers E J, Surawicz C M. Clostridium dificile infection. Lancet 2008;371:1486-1488
2. Ananthakrishnan A N, McGinley E L, Binion D G. Excess hospitalisation burden associated with Clostridium dificile in patients with inflammatory bowel disease. Gut 2008;57:205-210
3. Bajaj JS, Ananthakrishnan A N, Hafeezullah M et al. Clostridium dificile is associated with poor outcomes in patients with cirrhosis: a national and tertiary care center perspective. Am J Gastroenterol 2010;105:106-113 (this issue).
4. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26-42.
5. Vanjak D, Girault G, Branger C et al. Risk factors for Clostridium difcile infection in a hepatology ward. Infect Control Hosp Epidemiol 2007; 28:202-204
6. McDonald L C, Killgore G E, Tompson A et al. An epidemic, toxin gene-variant strain of Clostridium dificile. N Engl J Med 2005;353:2433-2441
7. Loo V G, Poirier L, Miller M A et al. A predominantly clonal multi-institutional outbreak of Clostridium difcile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449
8. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Aflairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829
9. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32: 142-153 (Pubitemid 30039459)
10. Fernandez J, Navasa M, Gomez J et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norf oxacin prophylaxis. Hepatology 2002;35:140-148
11. Acevedo J, Fernandez J, Castro M et al. Current eficacy of recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection. J Hepatol 2009;50 (Suppl 1): S5 (abstract).
12. Gines P, Rimola A, Planas R et al. Norfoxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results ofla double-blind, placebo-controlled trial. Hepatology 1990;12:716-724
13. Llach J, Rimola A, Navasa M et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance oflascitic fluid protein concentration. Hepatology 1992; 16: 724-727
14. Grange J D, Roulot D, Pelletier G et al. Norfoxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites \-a double-blind randomized trial. J Hepatol 1998;29:430-436
15. Guarner C, Sola R, Soriano G et al. R isk o fla first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999;117:414-419
16. Terg R, Fassio E, Guevara M et al. Ciprofoxacin in primary prophylaxis of spontaneous bacterial peritonitis. A randomized, placebo-controlled study. J Hepatol 2008; 48: 774-779
17. Fernandez J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824
18. Cunningham R, Dale B, Undy B et al.Proton pump inhibitors as a risk factor for Clostr idium dificile diar rhoea. J Hosp Infe ct 2003; 54: 243-245
19. Dial S, Alrasadi K, Manoukian C et al. R isk of Clostridium dificile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-38
20. Yearsley K A, Gilby L J, Ramadas A V et al. Proton pump inhibitor therapy is a risk factor for Clostridium dificile-associated diarrhoea. Aliment Pharmacol Ter 2006;24:613-619
21. Dial S, Delaney JA, Schneider V et al. Proton pump inhibitor use and risk of community-acquired Clostridium dificile-associated disease def ned by prescription for oral vancomycin therapy. CMAJ 2006;175:745-748
22. Lowe D O, Mamdani M M, Kopp A et al.Proton pump inhibitors and hospitalization for Clostridium dificile-associated disease: a population-based study. Clin Infect Dis 2006;43:1272-1276
23. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk offenteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-2056
24. Surawicz C M. The acid test: is proton pump inhibitor therapy an independent risk factor for Clostridium dificile-associated disease? Gastroenterology 2007;133:355-357
25. Nerandzic M M, Pultz M J, Donskey C J. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium dificile infection. Antimicrob Agents Chemother 2009;53:4133-4137
26. Choudhry M N, Soran H, Ziglam H M. Overuse and in appropriate prescribing of proton pump inhibitors in patients with Clostridium dificile-associated disease. QJM 2008; 101: 445-448
27. Kalaitzakis E, Bjornsson E. Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2008; 20:512-518
28. Macdougall B R, Williams R. A controlled clinical trial of cimetidine in the recurrence of variceal hemorrhage: implications about the pathogenesis of hemorrhage. Hepatology 1983; 3: 69-73.
29. Alaniz C, Mohammad R A, Welage L S. Continuous infusion of pan to prazole with octreotide does not improve management of variceal hemorrhage. Pharmacotherapy 2009; 29: 248-254
30. Garg P K, Sidhu SS, Bhargava D K. Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Double-blind randomized study. Dig Dis Sci 1995; 40: 1569-1574
31. Shaheen N J, Stuart E, Schmitz SM et al. Pantoprazole reduces the size of postbanding ulcers affer variceal band ligation: a randomized, controlled trial. Hepatology 2005;41:588-594